Tracy Spradlin individually and on behalf of all others similarly situated v. Elanco Animal Health, Inc.; Susan Kraus-Silfen v. Elanco Animal Health, Inc., Chewy, Inc., Petco Health and Wellness Company, Inc., PetMed Express, Inc., Tractor Supply Company, PetSmart, Inc.

District Court, S.D. Indiana·Decided September 17, 2026·No. 1:25-cv-00168·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION

TRACY SPRADLIN individually and on ) behalf of all others similarly situated, ) ) Plaintiffs, ) ) v. ) No. 1:24-cv-01299-JRO-MG ) ELANCO ANIMAL HEALTH, INC., ) ) Defendant. )

SUSAN KRAUS-SILFEN, ) ) Plaintiff, ) ) v. ) No. 1:25-cv-00168-JRO-MG ) ELANCO ANIMAL HEALTH, INC., ) CHEWY, INC., ) PETCO HEALTH AND WELLNESS ) COMPANY, INC., ) PETMED EXPRESS, INC., ) TRACTOR SUPPLY COMPANY, ) PETSMART, INC., ) ) Defendants. )

ORDER GRANTING UNOPPOSED MOTION FOR PRELIMINARY CLASS APPROVAL Named Plaintiffs Tracy Spradlin and Susan Kraus-Silfen (collectively, the "Named Plaintiffs," and, collectively, with the other members of the Settlement Class (the "Settlement Class Members" or "Class Members"), on the one hand, and Elanco Animal Health, Inc; Chewy, Inc.; Petco Health and Wellness Company, Inc.; Petmed Express, Inc.; Tractor Supply Co. (collectively with its wholly-owned subsidiary, Petsense LLC, to which the substantive allegations in the underlying complaints are directed); and PetSmart, Inc. (collectively, "Defendants"), on the other hand, have entered into a Class Action Settlement

Agreement and Release dated May 11, 2026, and the First Amendment to Settlement Agreement dated August 27, 2026, (altogether the "Settlement Agreement") to settle the above-captioned litigation ("Litigation"). Named Plaintiffs filed an Unopposed Motion for Entry of Preliminary Approval Order ("Motion") pursuant to Federal Rule of Civil Procedure 23(e). Dkt. 247.1 Defendants do not oppose the motion. Id. For the reasons stated below, Named Plaintiffs' motion for preliminary approval, dkt. [247], is GRANTED.

I. FACTS AND BACKGROUND2 These are two antitrust actions related to Elanco Animal Health Inc.'s ("Elanco") topical flea and tick products for dogs and cats, Advantix Products, which contains Imidacloprid as the active ingredient. Plaintiffs allege that Defendants conspired to sell only Elanco's Advantix Products and exclude generic brand Imidacloprid topical flea and tick products. Plaintiffs Tracy Spradlin and Susan Kraus-Silfen, purported class representatives, filed separate

1 Unless otherwise stated, docket citations are to the docket of Case No. 1:25-cv-168. 2 The Order incorporates the defined terms set forth in the Settlement Agreement and Release, dkt. 247-2, and the First Amendment to Settlement Agreement, dkt. 274-1. Terms and phrases used in this Preliminary Approval Order not otherwise defined herein shall have the same meanings ascribed to them in the Settlement Agreement. actions but have negotiated a global settlement with Defendants that would resolve both lawsuits.3 A. Antitrust Allegations

Elanco produces and manufactures Advantix Products. Dkt. 217-2 at 3. Plaintiffs allege a market comprised solely of topical, Imidacloprid-based flea and tick products, and that Elanco was the only participant in this market from 2002 to 2017, allowing it to obtain "brand recognition in the market and entrenched relationships with veterinarians, pet retails, and consumers." Id. When true generic Imidacloprid-based competitors entered the market in 2017, Elanco took two steps to promote its brand that Plaintiffs allege were anticompetitive. Id. First, Elanco entered into a series of agreements with pet specialty

retailers: Chewy, Inc. ("Chewy"); Petco Health and Wellness Company, Inc. ("Petco"); PetMed Express, Inc. ("PetMed"); Petsense LLC ("Petsense"); and PetSmart LLC ("Petsmart") (collectively the "Pet Specialty Retailers" and Defendants herein). Id. at 3–4. Those agreements incentivized retailers to refrain from selling generic Imidacloprid topicals by offering a discount on Elanco's product (the "Imidacloprid Exclusivity Discount"). Id. Plaintiffs allege this scheme

3 In light of the parties' settlement, Plaintiffs' motion to file a consolidated amended class action complaint, dkt. 212, was denied as moot, dkts. 218 & 239. This Order, however, summarizes the allegations as raised in the proposed consolidated amended class action complaint, dkts. 213 (sealed) & 217-2 (redacted), and summarized in the Settlement Agreement, dkts. 247-2 & 274-1. The Court is cognizant of the fact that, but-for settlement, the Court would have considered whether to allow the case to proceed under the consolidated amended class action complaint. The proposed consolidated amended class action complaint, therefore, best encapsulates Plaintiff's contentions, which the parties have decided to settle. "prolonged Elanco's preexisting monopoly on the Imidacloprid topical market, exploiting the market's high barriers to entry and maintaining Advantix's resulting supra-competitive pricing." Id. at 4.

Second, Elanco implemented a minimum advertised price policy. Id. at 5. This policy "guarante[ed] the Retailers' profit margins by eliminating price competition." Id. In other words, Retailers could not offer the Advantix Products at a lower price than their competitors. Plaintiffs allege this amounted to a "coordinated scheme of exclusive dealing and price-fixing" with Elanco acting as ringmaster. Id. at 5–6. Plaintiffs say that these two strategies insulated Advantix Products from price competition, both from generic products with the same active ingredient

and from Pet Specialty Retailers seeking to underprice one another to gain customers. As a result, consumers paid higher prices for Advantix Products. Id. at 6. Plaintiff Tracy Spradlin purchased Advantix Products from PetSmart in 2021 and from Petco in 2023. Plaintiff Susan Kraus-Silfen purchased Advantix Products online from Chewy four times between March 2020 and June 2024. Id. at 7. On behalf of themselves and similarly-situated consumers, Spradlin and

Kraus Silfen brought separate suits against Elanco and the Pet Specialty Retailers alleging violations of federal and state antitrust laws for the alleged conspiracy. See dkt. 249 at 4–5. B. The Tevra Litigation The day after Spradlin filed her case, a jury in a comparable antitrust suit against Elanco's predecessor, Bayer LLC, ruled in Bayer's favor. Dkt. 249 at 4

(citing Verdict Form, Tevra Brands LLC v. Bayer HealthCare LLC ("Tevra"), No. 19-cv-4312, Dkt. No. 485 (N.D. Cal. Aug. 1, 2024)). The jury found that the plaintiffs there failed to establish a relevant antitrust market, an essential element of the antitrust claims. Id. at 2. This instant matter has been styled as "copycat" litigation to the Tevra case. Id. at 2. The failure of the Tevra plaintiffs to establish a relevant market suggested Plaintiffs here may face similar challenges, exposing a possible weakness in their case. See id. at 4–5. C. Procedural History

All parties vigorously litigated the case: the parties engaged in motions practice spanning October 2024 to March 2026; plaintiffs' expert prepared a 115- page expert report opining damages could run as high as $48.5–$72.3 million, dkt. 267-1 at 82; document production included more than 200,000 documents from Defendants, which Plaintiffs reviewed with the use of technology assisted review and artificial intelligence, dkt. 247-1 ¶ 14; and the magistrate judge presided over a multitude of discovery disputes, status conferences, and settlement conferences, e.g. dkts. 65, 91, 101, 110, 111, 131, 138, 145, 160,

171, 178, 181, 194, and 209. Plaintiffs maintain that, should the case move forward, more work remains to be done, including "further discovery, document production, depositions, expert discovery, more motion practice, trial, and appeal." Dkt. 247-1 ¶ 15. In spring of 2026, the parties reached a settlement agreement. See dkt. 239. D. Proposed Settlement

Free access — add to your briefcase to read the full text and ask questions with AI

Tracy Spradlin individually and on behalf of all others similarly situated v. Elanco Animal Health, Inc.; Susan Kraus-Silfen v. Elanco Animal Health, Inc., Chewy, Inc., Petco Health and Wellness Company, Inc., PetMed Express, Inc., Tractor Supply Company, PetSmart, Inc., (S.D. Ind. 2026).

Tracy Spradlin individually and on behalf of all others similarly situated v. Elanco Animal Health, Inc.; Susan Kraus-Silfen v. Elanco Animal Health, Inc., Chewy, Inc., Petco Health and Wellness Company, Inc., PetMed Express, Inc., Tractor Supply Company, PetSmart, Inc. (Tracy Spradlin individually and on behalf of all others similarly situated v. Elanco Animal Health, Inc.; Susan Kraus-Silfen v. Elanco Animal Health, Inc., Chewy, Inc., Petco Health and Wellness Company, Inc., PetMed Express, Inc., Tractor Supply Company, PetSmart, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

General Telephone Co. of Southwest v. Falcon
457 U.S. 147 (Supreme Court, 1982)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Ortiz v. Fibreboard Corp.
527 U.S. 815 (Supreme Court, 1999)
Gomez v. St. Vincent Health, Inc.
649 F.3d 583 (Seventh Circuit, 2011)
Rosario v. Livaditis
963 F.2d 1013 (Seventh Circuit, 1992)
Isby v. Bayh
75 F.3d 1191 (Seventh Circuit, 1996)
Muro v. Target Corp.
580 F.3d 485 (Seventh Circuit, 2009)
Arreola v. Godinez
546 F.3d 788 (Seventh Circuit, 2008)
James Hayes v. Accretive Health, Incorporated
773 F.3d 859 (Seventh Circuit, 2014)
Bell v. PNC Bank, National Ass'n
800 F.3d 360 (Seventh Circuit, 2015)
Kleen Products LLC v. International Paper Co.
831 F.3d 919 (Seventh Circuit, 2016)
Andrea Santiago v. City of Chicago
19 F.4th 1010 (Seventh Circuit, 2021)